Updated:
Eir Ventures
Eir Ventures backs Nordic life-science startups with a team of PhDs and MDs, translating innovation into marketed products from Stockholm and Copenhagen.
Eir Ventures
a Life Science Venture Group in the Nordics | Eir Ventures aims to use a strong Nordic base and focus as a foundation to help leverage the power in current global medical research, thus being part in bringing innovative medicine to the patients.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Nybrogatan 6, 114 34 Stockholm, Sweden
Additional offices
Copenhagen, Denmark
Sector focus
Frequently asked questions
What is Eir Ventures' investment focus?
Eir Ventures targets life-science companies across the Nordics, from early-stage seed and start-up rounds through to expansion capital. Its portfolio spans therapeutics, medtech, and digital health, with the firm aiming to advance programs into clinical trials and toward regulatory approval.
How does Eir Ventures structure its portfolio involvement?
The firm takes an active ownership role, frequently placing team members on the boards of its portfolio companies and occasionally stepping into interim CEO positions. This operational posture is intended to guide start-ups from laboratory-stage innovation through to commercial partnerships and product launches.
Does Eir Ventures co-invest with other firms?
Yes. The firm participates in international syndicates that include pharmaceutical corporations and venture investors located in the Nordics, Europe, and the United States. These co-investment structures help portfolio companies access later-stage capital and global commercialization channels.
Which geographies does Eir Ventures cover?
Eir Ventures concentrates on the Nordic region, with investment operations run from offices in Stockholm and Copenhagen. While the sourcing is regionally focused, the firm's syndication network extends into broader European and US life-science ecosystems.
What is Eir Ventures' track record on exits and regulatory milestones?
The firm reports more than 20 successful exits from its portfolio, alongside more than 20 clinical programs advanced and multiple products that have reached marketing approval. It also notes a history of deals and collaborations with pharmaceutical companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: